Single enzyme flaw reveals how neurons die in dementia

Scientists have identified a tiny structural flaw in a single enzyme that triggers neuron death in a rare form of childhood dementia — and the discovery is reshaping how researchers think about brain degeneration more broadly.

The enzyme in question is glutathione peroxidase 4, or GPX4. In healthy neurons, it works like a molecular lifeguard, positioning itself along the inner surface of the cell membrane to neutralize harmful molecules called lipid peroxides before they can cause damage. But when a single genetic mutation alters GPX4's structure — changing what researchers describe as its "fin" — the enzyme can no longer anchor itself properly in the membrane. Lipid peroxides accumulate unchecked, the membrane becomes unstable, and the neuron dies through a process called ferroptosis.

"GPX4 is a bit like a surfboard," explains Prof. Marcus Conrad, who led the research at Helmholtz Munich. "With its fin immersed into the cell membrane, it rides along the inner surface and swiftly detoxifies lipid peroxides as it goes." When that fin is malformed, the surfboard can't stay in position.

The discovery began with three children in the United States, all carrying the same genetic mutation — R152H — and all developing severe dementia in early childhood. Researchers grew neurons from cells taken from one of these children, then introduced the same mutation into mice to observe what happens in a living brain. The results were striking: the mice developed motor problems, lost significant numbers of neurons in the cortex and cerebellum, and showed signs of neuroinflammation. The protein patterns in their brains matched those seen in Alzheimer's disease patients.

Why This Matters Beyond Rare Mutations

Here's where the finding gets broader. The protein changes that occur when GPX4 fails are nearly identical to what happens in common forms of dementia like Alzheimer's. This suggests ferroptosis — this particular type of cell death — may not be a side effect of dementia but a primary driver of it. Until now, dementia research has focused heavily on amyloid plaques, protein clumps that accumulate in aging brains. This work points to something earlier in the process: damage to cell membranes that sets neurodegeneration in motion.

Early laboratory tests show that blocking ferroptosis can slow neuron death in both cell cultures and mice with non-functional GPX4. It's not yet a treatment — the researchers are careful to emphasize this remains basic research — but it's a proof of concept that the pathway can be interrupted.

"It has taken us almost 14 years to link a yet-unrecognized small structural element of a single enzyme to a severe human disease," Conrad notes. The project involved researchers across genetics, structural biology, stem cell research, and neuroscience at institutions worldwide. That kind of sustained, collaborative work is what it takes to understand something as complex as dementia.

The next steps would involve developing genetic or molecular strategies to stabilize GPX4's protective function. For now, this research has opened a door that might eventually lead somewhere very different from where dementia research has been looking.